Health

Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale

Janux is working with adviser after drawing takeover interest
Shares surge up to 22% Wednesday to quadruple this year

Janux Therapeutics Inc. is exploring options after receiving takeover interest from larger pharmaceutical companies. — Janux Therapeutics Inc. is exploring options after receiving takeover interest from larger pharmaceutical companies.
Photographer: Loic Venance/AFP/Getty Images

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Dinesh Nair, Michelle F Davis, and Manuel Baigorri

April 10, 2024 at 5:41 PM UTC

Updated on

April 10, 2024 at 8:45 PM UTC

This article is for subscribers only.

Drugmaker Janux Therapeutics Inc. is exploring options, including a potential sale, after receiving takeover interest from larger pharmaceutical companies, people with knowledge of the matter said.

The company, which develops tumor-activated immunotherapies to treat cancer, is working with a financial adviser to evaluate possibilities including a sale, according to the people, who asked not to be identified discussing confidential information.